source
- Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3Vaderis is hoping that engasertib will become the first approved medicine for hereditary hemorrhagic telangiectasia, a rare condition that can cause spontaneous bleeding.BioSpace · 6h ago↗ source
- STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?Biotech companies don’t hide or obfuscate strong data.STAT · 8h ago↗ source
- Tenax Therapeutics' heart failure drug TNX-103 misses primary endpoint in Phase 3, shares plunge 85%Tenax Therapeutics announced that its investigational heart failure drug TNX-103 failed to meet the primary efficacy endpoint in the Phase 3 LEVEL trial. The trial, which enrolled patients with pu…BioSpace